Lupin acquires Symbiomix Therapeutics

MUMBAI, India — Lupin’s U.S. subsidiary’s latest acquisition is set to strengthen its pipeline for gynecologic drugs. The company has acquired Symbiomix Therapeutics for $150 million, which includes an upfront payment of $50 million and closed today.

With the acquisition, Lupin brings into its portfolio the Symbiomix’s Solosec franchise, expanding its women’s health specialty business, currently anchored by Lupin’s Methergine tablets. Solosec oral granules — a single-dose treatment for bacterial vaginosis — was approved by the Food and Drug Administration in mid-September and is set to be launched mid-2018. Having been designated by the FDA as a Qualified Infectious Disease Product, Solosec is eligible for 10 years of U.S. exclusivity, the company said.

“We are delighted to complete the acquisition of Symbiomix and its Solosec brand, which immediately expands Lupin’s U.S. women’s health specialty business into the highly-complementary gynecological infection sector,” Lupin CEO Vinita Gupta said. “This transaction is an important milestone in the evolution of our Specialty business and gives Lupin a new therapeutic to bring to obstetricians and gynecologists to treat a serious health condition they see frequently in their practices.”